Mood-Stabilizers Target the Brain Arachidonic Acid Cascade
Open accessThe DOI matches its OpenAlex record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Bipolar disorder (BD) is a severe psychiatric illness characterized by recurrent manic and depressive episodes, without a characteristic neuropathology or clear etiology. Drugs effective in BD target many key signaling pathways in animal and cell studies. However, their mode of action in the BD brain remains elusive. In the rat brain, some of the mood stabilizers effective in treating mania (lithium, carbamazepine, valproate) or depression (lamotrigine) in BD are reported to decrease transcription of cytosolic phospholipase A(2) and cyclooxygenase-2 and to reduce levels of AP-2 and NF-kappaB, transcription factors of the two enzymes. The anti-manic drugs also decrease arachidonic acid (AA) turnover in brain phospholipids when given chronically to rats. Thus, drugs effective in BD commonly target AA cascade kinetics as well as AA cascade enzymes and their transcription factors in the rat brain. These studies suggest that of BD is associated with increased AA signaling in the brain. Developing therapeutic agents that suppress brain AA signaling could lead to additional treatments for BD. In this review, we discuss the mechanisms of action of mood stabilizers and the effects of docosahexaenoic acid on AA cascade enzymes in relation to BD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817 · cited 1×
“A portion of the AA released by cPLA2 is metabolized to bioactive eicosanoids by cyclooxygenase (COX-1 or COX-2), lipoxygenase, or cytochrome P450 epoxygenase enzymes [27].”
BackgroundPhiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“Studies also indicate that VPA directly inhibits histone deacetylase [74].”
BackgroundCalabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Affective disorders and suicide risk: a reexamination
Bostwick, J. M., & Pankratz, V. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1925 · Cited by 878 · cited 1×
“5 % of the United States population [1] and that BD patients have a 5-to-17 fold increased risk of suicide relative to the general population [2].”
BackgroundOmega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Baum, A. E., Akula, N., Cabanero, M., Cardona, I., Corona, W., Klemens, B., Schulze, T. G., Cichon, S., Rietschel, M., Nöthen, M. M., et al. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002012 · Cited by 700 · cited 1×
“Several hypotheses have been proposed to explain BD based on alterations in signal transduction pathways [3]: reduced levels of neurosurvival factors [4], atrophy in brain regions [4–8] and involvement of many genes[9,10].”
BackgroundBanasr, M., Chowdhury, G. M. I., Terwilliger, R., Newton, S. S., Duman, R. S., Behar, K. L., & Sanacora, G. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.106 · Cited by 458
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder
Kim, Y.-K., Jung, H.-G., Myint, A.-M., Kim, H., & Park, S.-H. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.02.018 · Cited by 375
Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.
O'Brien, S. M., Scully, P., Scott, L. V., & Dinan, T. G. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.11.015 · Cited by 285
Frontal lobe gray matter density decreases in bipolar I disorder
Lyoo, I. K., Kim, M. J., Stoll, A. L., Demopulos, C. M., Parow, A. M., Dager, S. R., Friedman, S. D., Dunner, D. L., & Renshaw, P. F. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.10.017 · Cited by 263
Ghelardoni, S., Tomita, Y. A., Bell, J. M., Rapoport, S. I., & Bosetti, F. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.05.012 · Cited by 95
Self-citationNew data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder
Calabrese, Jr., Rapport, D., Youngstrom, E., Jackson, K., Bilali, S., & Findling, R. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.12.003 · Cited by 46
Cited by
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients
Rao, J. S., Keleshian, V. L., Klein, S., & Rapoport, S. I. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.55 · Cited by 304
Self-citationNeurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder
Pfaffenseller, B., Fries, G. R., Wollenhaupt-Aguiar, B., Colpo, G. D., Stertz, L., Panizzutti, B., Magalhães, P. V., & Kapczinski, F. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811981 · Cited by 68
VEGF regulates antidepressant effects of lamotrigine
Sun, R., Li, N., & Li, T. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.010 · Cited by 22
Metadata
- Authors
- Rao, J. S., & Rapoport, S. I.
- Venue
- Current Molecular Pharmacology
- Publisher
- Bentham Science Publishers
- Published
- 2009-06-01
- Volume
- 2
- Issue
- 2
- Pages
- 207-214
- ISSN
- 1874-4672 (ISSN-L)
- OpenAlex
- W2009348063
- Cited by
- 58
- References
- 13
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.